BioSpace News Archive

Transparency Market Research has published a new report titled, ‘Global Bone Graft Substitutes Market.’ According to the report, the global bone graft substitutes market was valued at US$ 2.9 Bn in 2019 and is projected to expand at a CAGR of ~3% from 2020 to 2030.

Vifor Pharma and Cara Therapeutics, Inc. announced that both companies have signed a license agreement for commercialization of Korsuva Injection for the treatment of chronic kidney disease-associated pruritus in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement.

Nine-month results: Order intake1 up 37.8 percent; sales revenue up 25.2 percent; underlying EBITDA1 margin climbs to 29.1 percent

NANOBIOTIX, a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, announced four clinical and/or pre-clinical presentations to be delivered at The Society for Immunotherapy of Cancer 35th Anniversary Annual Meeting.

Open Orphan plc, a rapidly growing specialist CRO pharmaceutical services company, which is the world leader in the testing of vaccines and antivirals using human challenge studies, is pleased to announce the signing of a contract by hVIVO, a subsidiary of Open Orphan, with the UK Government to develop a COVID-19 human challenge study model.

Full Class II De Novo FDA Submission seeking clearance of the Parsortix system for metastatic breast cancer has successfully completed FDA administrative review

AmacaThera Inc. is pleased to announce approval from Health Canada to proceed to a Phase 1 clinical trial with its lead asset, a long-acting anesthetic formulation for the treatment of post-surgical pain.

Dr. Reddy’s Laboratories Ltd. announced the re-launch of over-the-counter Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalents of Original Strength and Maximum Strength Pepcid AC®, in the U.S. market, as approved by the U.S. Food and Drug Administration.

AM-Pharma B.V., an emerging leader focused on the treatment of kidney disease, sepsis and organ injury, announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer and Teun van de Laar, Ph.D., as Vice President Manufacturing and Supply Chain Management.

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced that Prof. Arndt Rolfs, the Company’s Chief Executive Officer and founder, has decided to step down as CEO of CENTOGENE as of October 20, 2020, and that Andrin Oswald, M.D., will join the Company as CEO on December 1, 2020.